Biotech Values

[DewDiligence]

Re: Otamixaban

[From SNY’s PR in #msg-41012818]: …otamixaban displayed clinically meaningful activity on the primary endpoint from the threshold dose of 0.070 mg/kg/h, the second tested dose, with a consistent antithrombotic effect up to the 5th highest tested dosage.

[exwannabe]: am I brain dead or anal on questioning what this says?

Good eye! This sentence must contain a typo because the second dose tested, 0.70/kg/h was the fifth-highest of the six doses tested. I think the word “5th” is not supposed to be there—i.e. the sentence is supposed to read, “…with a consistent antithrombotic effect up to the highest tested dosage.” Regardless of how this sentence is interpreted, it does not alter my assessment in the prologue of #msg-41012818 that the otamixaban program is a day late and a dollar short.